Pharmacom Labs Letros 2.5mg

Pharmacom Labs Letros 2.5mg | Oral Letrozole Formulation

Pharmacom Labs Letros is an orally active, non-steroidal Type II Aromatase Inhibitor (AI) containing 2.5mg of Letrozole per unit dose. Functioning via competitive, reversible binding to the heme subunit of the cytochrome P450 aromatase ($CYP19A1$) enzyme, Letrozole prevents the peripheral enzymatic conversion of circulating androgens (such as testosterone and androstenedione) into estrogens (estradiol and estrone).

Recognized as one of the most potent aromatase inhibitors available, Letrozole is capable of suppressing circulating serum estrogen concentrations by up to 98% at standard pharmacological dosages.

Manufactured by Pharmacom Labs under laboratory production standards with strict batch verification protocols to ensure content uniformity and precise dosing. Store at controlled room temperature (15°C to 25°C), protected from direct light exposure, excessive thermal environments, and ambient humidity.

Product Attribute Table